BOSTON, MA -- Bio-IT World 2012 -- NVIDIA today announced that BGI, the world's largest genomics institute, is launching a service that will enable researchers worldwide to perform affordable next-generation sequencing (NGS) bioinformatics analysis in the cloud.
The new "EasyGenomics" service from Shenzhen, China-based BGI combines an intuitive user interface with BGI's automated pipeline analysis, software and tools. These are integrated with the industry's largest sequencing platform to provide everything biologists, bioinformaticists and, ultimately, physicians need to submit and receive an automated analysis of DNA sequencing data.
Accelerated by NVIDIA GPUs, which speed the processing of the analysis of DNA big data from days to hours compared with a CPU-based system, EasyGenomics dramatically expands the availability of advanced genomics research capabilities to researchers around the world, bringing science closer to an era of affordable and viable personalized medicine.
BGI is launching a limited free trial of the new service today for qualified biologists and bioinformaticists at the 2012 Bio-IT World Conference and Expo. To learn more or to apply, visit the EasyGenomics website.
"By enabling larger numbers of researchers to accelerate DNA sequencing data more easily and affordably, we hope to help facilitate the use of genomics for clinical diagnostics as a practical component of health care, as well as for complex disease research," said Dr. Lin Fang, vice president at BGI. "GPU acceleration enables scientists to analyze DNA sequencing data faster than was ever possible, reducing the time from five days to just five hours. Once fully deployed in the cloud, we anticipate EasyGenomics could one day revolutionize genomics research."
The EasyGenomics cloud service features hybrid computing systems powered by NVIDIA® Tesla® M2070 and M2075 GPUs, which accelerate the DNA sequencing data analysis in conjunction with system CPUs. BGI plans to upgrade the EasyGenomics service with hundreds of additional NVIDIA Tesla GPUs when it is fully deployed, at which time it is expected to support thousands of users.
"This could be the year of the $1,000 genome due to rapid decline in sequencing costs. We will soon be drowning in a deluge of data from the genome sequencers," said Sumit Gupta, senior director of the Tesla business at NVIDIA. "BGI's EasyGenomics service uses the power of GPU computing to provide an affordable and easy-to-use method for scientists to crunch through this new genomics big data problem and get us that much closer to effective and affordable individualized treatments."
BGI does groundbreaking work in genomic sequencing of a wide range of life forms -- ranging from plants and E. coli to the giant panda -- to develop better medicines, improve healthcare and develop genetically enhanced food. Headquartered in Shenzhen, China, with affiliates in Cambridge, Mass., and Copenhagen, Denmark, BGI's goal is to make leading-edge genomic science highly accessible. More information about BGI is available at www.en.genomics.cn.
About NVIDIA Tesla GPUs
NVIDIA Tesla GPUs are massively parallel accelerators based on the NVIDIA CUDA® parallel computing platform. Tesla GPUs are designed from the ground up for power-efficient, high performance computing, computational science and supercomputing, delivering dramatically higher application acceleration for a range of scientific and commercial applications than a CPU-only approach. Today, Tesla GPUs power three of the world's top five supercomputers.
More information about NVIDIA Tesla GPUs is available at the Tesla website. To learn more about CUDA or download the latest version, visit the CUDA website. More NVIDIA news, company and product information, videos, images and other information is available at the NVIDIA newsroom. You can also follow us on Twitter (@NVIDIATesla).
Certain statements in this press release including, but not limited to statements as to: the impact and benefits of NVIDIA Tesla GPUs; and the effects of the company's patents on modern computing are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the reports NVIDIA files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the fiscal period ended January 29, 2012. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
© 2012 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, CUDA, and Tesla are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability, and specifications are subject to change without notice.